Monetizing the Sun: How UVB Therapy is Taking Over Longevity Clinics

BAINBRIDGE ISLAND, WA – November 03, 2026 – In my days poring over corporate earnings reports as a market analyst, I learned that the most lucrative business models often involve packaging something abundant and making it precise, measurable, and proprietary. Today, as a journalist and a mother who spends half her time chasing kids out into the sunshine, I find those two worlds colliding in a fascinating way. The asset being packaged and sold now isn't software or pharmaceuticals—it is sunlight.

Solius Labs, a health technology company based in Bainbridge Island, Washington, recently announced the nationwide rollout of its personalized UVB light therapy device across a growing network of premier longevity clinics and medically driven health clubs. Since its commercial launch in June 2026, the technology has been integrated into facilities like Extension Health in New York City, WellWay in the Midwest and Florida, Monarch Athletic Club in Los Angeles and Miami, and Humanaut Health across Texas, Florida, and California.

The premise is as simple as it is ambitious: modern life keeps us indoors, depriving us of what the company calls the "fourth pillar of health." By isolating a specific narrow spectrum of UVB light, Solius aims to deliver the physiological benefits of sunshine—ranging from natural vitamin D synthesis to mood regulation—without the unpredictable risks of a day at the beach.

High-Tech Sunlight: From Dermatology to Luxury Wellness

Phototherapy is not a new concept. For decades, dermatologists have utilized ultraviolet light to treat severe skin conditions like psoriasis, eczema, and vitiligo. However, these treatments have traditionally been confined to clinical wards, requiring strict physician oversight and prescription access. What makes this recent rollout noteworthy is the aggressive pivot from reactive dermatology to proactive wellness and longevity.

The regulatory pathway here is particularly telling. When the FDA cleared the Solius Pro device (K252960) in January 2026, it did not simply approve another medical lamp. The agency established an entirely new product code, SGZ ("Ultraviolet Lamp Products"), classifying it as a Class II over-the-counter medical device. This unprecedented clearance allows the hardware to be marketed and used without a prescription, effectively tearing down the barrier between clinical phototherapy and the mainstream consumer longevity market.

"UVB is difficult to dose even on a sunny summer day, and for people who spend their days indoors or live in northern climates, it rarely reaches them at all, eliminating the physiologic benefits sunshine provides," said Chris Kiple, Chief Executive Officer of Solius Labs. "Solius isolates UVB light and delivers it in a personalized, measured dose, so people can access the powerful health benefits of this narrow spectrum safely, all year long."

The technology relies on a 293-nanometer LED spectrum, optimized specifically for vitamin D synthesis rather than the 311-313 nanometer range typically used in traditional dermatological devices. To mitigate the inherent risks of ultraviolet radiation, the system utilizes a proprietary optical skin sensor. A one-time measurement in the companion mobile app calculates an individualized, sub-erythemal dose—meaning it stops just short of causing a sunburn.

"We measure everything that drives healthspan, and sunlight exposure is one of the most overlooked inputs," said Dr. Jonathann Kuo, Founder and CEO of Extension Health, a longevity practice offering advanced diagnostics like biological age testing. "Solius gives our patients a precise, personalized dose of UVB, in our clinic and at home."

The Science of 'Natural' Vitamin D and Longevity Claims

As someone who inherently trusts data over marketing copy, the boldest claim in the company's recent announcement immediately caught my eye. Kiple noted that "real world data has shown UVB light can extend your life expectancy more than 2.1 years."

It is a compelling headline, though a closer look at the research reveals a more nuanced reality. The 2.1-year life extension figure is drawn from broader epidemiological studies on general sunlight exposure and all-cause mortality, rather than a specific, controlled clinical trial tracking mortality rates of Solius device users. However, the biochemical mechanisms the company is leveraging are deeply rooted in established endocrinology.

When UVB light penetrates the epidermis, it triggers a cascade of systemic biological responses. The most well-known is the synthesis of vitamin D3, but the process also stimulates the endogenous production of nitric oxide (which supports cardiovascular health by dilating blood vessels), serotonin, dopamine, and beta-endorphins.

"At Monarch, we test, we don’t guess, and vitamin D is one of the most common gaps we find, even in members who live in sunny Los Angeles. Supplements help, but they’re one-size-fits-all," said Dr. Ryan Greene, Co-Founder and Medical Director of Monarch Athletic Club. "Solius lets us give members a personalized, measured dose of UVB matched to their skin type, so they’re making vitamin D the way the body was designed to, without the guesswork or the sunburn."

The debate between oral supplementation and synthesized vitamin D is a fierce one in medical circles. Oral pills rely on the digestive tract and can be ineffective for individuals with malabsorption issues. Light-induced vitamin D synthesis, conversely, is self-regulating; the body naturally degrades excess previtamin D3 to prevent toxicity. A recent clinical study funded by the company demonstrated an average individual increase of 76% in serum vitamin D among participants using the device, all without visible skin damage.

Still, the intentional exposure to ultraviolet radiation remains a complex medical topic. One independent photobiology researcher I spoke with, who studies the long-term epidermal impacts of light therapy, noted that while the systemic benefits of controlled UVB are undeniable, they must be carefully weighed against cumulative skin cancer risks. The company addresses this by claiming its device delivers 12 times more biological benefit than the sun with 99% less UV risk, and 50% less total UV radiation than prescription narrowband devices. Built-in safeguards, including a dynamic distance sensor, mandatory eyewear verification, and an automatic 24-hour lockout between sessions, are designed to enforce this safety margin.

The Next Monetization Engine for Health Clubs

From a pure market perspective, the genius of the system lies in its B2B economics. Longevity clinics and high-end health clubs operate in a highly competitive, capital-intensive industry. To survive, they require high-margin, recurring revenue streams that do not linearly increase their labor costs.

Historically, adding a new medical therapy to a clinic meant hiring specialized staff, dedicating large treatment rooms, and navigating complex medical billing. This new wave of self-service medical devices fundamentally alters that equation.

The hardware is designed for complete autonomy. Because it is an FDA-cleared over-the-counter device, no physician oversight is required on-site. The app-guided sessions, which typically last only a few minutes, require absolutely no staff time. The physical footprint is minimal, requiring only a standard wall outlet and a small, dedicated private space.

"We’re selective about what we bring into our clubs, and we look for what’s grounded in research and works in our members’ real lives," said Chris Schultheis, Co-Founder & CEO of WellWay. "Solius fits that approach. It’s safe, measured, and easy to fit into a club visit."

This operational efficiency translates to flexible monetization strategies for the operators. Clinics can bundle the therapy into premium membership tiers, sell it as an à la carte add-on, or charge per session. With no warm-up or cool-down periods required, a single device can support a massive daily throughput of users, maximizing the return on the initial hardware investment.

"Humanaut is built around adding healthy years," added Jim Donnelly, CEO and Co-Founder of Humanaut Health. "Personalized UVB light therapy fills a health gap most of our members didn’t know they had."

A New Market Segment in Photomedicine

As we watch this rollout unfold, it is clear that we are witnessing the creation of a distinct new sub-sector within the wellness economy. For years, the consumer light therapy market has been dominated by red light therapy (photobiomodulation) panels, which utilize entirely different wavelengths to target cellular energy and inflammation. Meanwhile, traditional medical phototherapy manufacturers like Daavlin have remained firmly entrenched in the prescription-only dermatology space.

By securing an over-the-counter clearance for a targeted UVB modality, a bridge has been built between the rigorous standards of medical devices and the frictionless accessibility of consumer biohacking. It is a fascinating economic case study in how regulatory strategy can unlock entirely new business models.

Whether this technology will truly add 2.1 years to our lives remains to be proven by decades of longitudinal data. But in the immediate term, the data shows a clear trend: the business of longevity is booming, and the commercialization of sunlight is proving to be a highly profitable frontier for the clinics that are quick enough to plug it in.